| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 3, 2026Next | Q4 2026 | After market close | 4.60 | 89.1 B |
Aug 26, 2026
"Not for distribution to United States news wire services or for dissemination in the United States."VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its previously announced private placements (together, the "Offering") for aggregate gross proceeds of C$15,223,109.
It was reported on August 25, that Elizabeth S Campbell, Executive Vice President at Cencora (NYSE:COR) executed a significant insider sell, according to an SEC filing. What Happened: After conducting a thorough
Aug 20, 2026
Aug 19, 2026
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.
RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.
Aug 14, 2026
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in
Aug 13, 2026
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.
Aug 12, 2026
Revenue hit $84.8 billion as GLP-1 sales surged 25% despite manufacturer price headwinds.
Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.
Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the "Company" or "Cencora") separate from the prime vendor agreement began moving outside the Company. The prime
Aug 11, 2026
S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.
Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $331 to $395.
